Literature DB >> 26997567

Advances in development of fluorescent probes for detecting amyloid-β aggregates.

Ming-Ming Xu1, Wen-Ming Ren2, Xi-Can Tang1, You-Hong Hu2, Hai-Yan Zhang1.   

Abstract

With accumulating evidence suggesting that amyloid-β (Aβ) deposition is a good diagnostic biomarker for Alzheimer's disease (AD), the discovery of active Aβ probes has become an active area of research. Among the existing imaging methods, optical imaging targeting Aβ aggregates (fibrils or oligomers), especially using near-infrared (NIR) fluorescent probes, is increasingly recognized as a promising approach for the early diagnosis of AD due to its real time detection, low cost, lack of radioactive exposure and high-resolution. In the past decade, a variety of fluorescent probes have been developed and tested for efficiency in vitro, and several probes have shown efficacy in AD transgenic mice. This review classifies these representative probes based on their chemical structures and functional modes (dominant solvent-dependent mode and a novel solvent-independent mode). Moreover, the pharmaceutical characteristics of these representative probes are summarized and discussed. This review provides important perspectives for the future development of novel NIR Aβ diagnostic probes.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26997567      PMCID: PMC4954760          DOI: 10.1038/aps.2015.155

Source DB:  PubMed          Journal:  Acta Pharmacol Sin        ISSN: 1671-4083            Impact factor:   6.150


  78 in total

Review 1.  Shedding light onto live molecular targets.

Authors:  Ralph Weissleder; Vasilis Ntziachristos
Journal:  Nat Med       Date:  2003-01       Impact factor: 53.440

2.  Increased neuronal endocytosis and protease delivery to early endosomes in sporadic Alzheimer's disease: neuropathologic evidence for a mechanism of increased beta-amyloidogenesis.

Authors:  A M Cataldo; J L Barnett; C Pieroni; R A Nixon
Journal:  J Neurosci       Date:  1997-08-15       Impact factor: 6.167

3.  Amyloid-β oligomer detection by ELISA in cerebrospinal fluid and brain tissue.

Authors:  Kim A Bruggink; Wesley Jongbloed; Elisanne A L M Biemans; Rob Veerhuis; Jurgen A H R Claassen; H Bea Kuiperij; Marcel M Verbeek
Journal:  Anal Biochem       Date:  2012-09-26       Impact factor: 3.365

4.  Advances of molecular imaging probes for the diagnosis of Alzheimer's disease.

Authors:  Ming Zhou; Xiaobo Wang; Zhiguo Liu; Lun Yu; Shuo Hu; Lizhang Chen; Wenbin Zeng
Journal:  Curr Alzheimer Res       Date:  2014-03       Impact factor: 3.498

Review 5.  Amyloid imaging using high-field magnetic resonance.

Authors:  Tomone Amatsubo; Daijiro Yanagisawa; Shigehiro Morikawa; Hiroyasu Taguchi; Ikuo Tooyama
Journal:  Magn Reson Med Sci       Date:  2010       Impact factor: 2.471

6.  Development of fluorescent probes that bind and stain amyloid plaques in Alzheimer's disease.

Authors:  Seung-Jin Jung; Seung-Hwan Park; Eun Je Lee; Jeong Hoon Park; Young Bae Kong; Jong Kook Rho; Min Goo Hur; Seung Dae Yang; Yong Dae Park
Journal:  Arch Pharm Res       Date:  2015-05-27       Impact factor: 4.946

7.  Curcumin labels amyloid pathology in vivo, disrupts existing plaques, and partially restores distorted neurites in an Alzheimer mouse model.

Authors:  M Garcia-Alloza; L A Borrelli; A Rozkalne; B T Hyman; B J Bacskai
Journal:  J Neurochem       Date:  2007-04-30       Impact factor: 5.372

8.  Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study.

Authors:  Victor L Villemagne; Samantha Burnham; Pierrick Bourgeat; Belinda Brown; Kathryn A Ellis; Olivier Salvado; Cassandra Szoeke; S Lance Macaulay; Ralph Martins; Paul Maruff; David Ames; Christopher C Rowe; Colin L Masters
Journal:  Lancet Neurol       Date:  2013-03-08       Impact factor: 44.182

9.  Phase 1 study of the Pittsburgh compound B derivative 18F-flutemetamol in healthy volunteers and patients with probable Alzheimer disease.

Authors:  Natalie Nelissen; Koen Van Laere; Lennart Thurfjell; Rikard Owenius; Mathieu Vandenbulcke; Michel Koole; Guy Bormans; David J Brooks; Rik Vandenberghe
Journal:  J Nucl Med       Date:  2009-07-17       Impact factor: 10.057

10.  Fluorescent 2-styrylpyridazin-3(2H)-one derivatives as probes targeting amyloid-beta plaques in Alzheimer's disease.

Authors:  Yong Dae Park; Jeong Hoon Park; Min Goo Hur; Sang Wook Kim; Jung-Joon Min; Seung-Hwan Park; Yung Joon Yoo; Yong-Jin Yoon; Seung Dae Yang
Journal:  Bioorg Med Chem Lett       Date:  2012-04-21       Impact factor: 2.823

View more
  5 in total

Review 1.  Current progress, challenges and future prospects of diagnostic and therapeutic interventions in Alzheimer's disease.

Authors:  K Rajasekhar; Thimmaiah Govindaraju
Journal:  RSC Adv       Date:  2018-06-29       Impact factor: 4.036

2.  Development and Optimization of a Fluorescent Imaging System to Detect Amyloid-β Proteins: Phantom Study.

Authors:  David Tes; Karl Kratkiewicz; Ahmed Aber; Luke Horton; Mohsin Zafar; Nour Arafat; Afreen Fatima; Mohammad Rn Avanaki
Journal:  Biomed Eng Comput Biol       Date:  2018-06-18

3.  Identification of Multicolor Fluorescent Probes for Heterogeneous Aβ Deposits in Alzheimer's Disease.

Authors:  Abhisek Mukherjee; Rabab Al-Lahham; Mark E Corkins; Sourav Samanta; Ann M Schmeichel; Wolfgang Singer; Phillip A Low; Thimmaiah Govindaraju; Claudio Soto
Journal:  Front Aging Neurosci       Date:  2022-02-03       Impact factor: 5.702

4.  Amphiphilic Distyrylbenzene Derivatives as Potential Therapeutic and Imaging Agents for Soluble and Insoluble Amyloid β Aggregates in Alzheimer's Disease.

Authors:  Liang Sun; Hong-Jun Cho; Soumyo Sen; Andres S Arango; Truc T Huynh; Yiran Huang; Nilantha Bandara; Buck E Rogers; Emad Tajkhorshid; Liviu M Mirica
Journal:  J Am Chem Soc       Date:  2021-07-02       Impact factor: 15.419

Review 5.  Advances in the development of imaging probes and aggregation inhibitors for alpha-synuclein.

Authors:  Ming-Ming Xu; Philip Ryan; Santosh Rudrawar; Ronald J Quinn; Hai-Yan Zhang; George D Mellick
Journal:  Acta Pharmacol Sin       Date:  2019-10-04       Impact factor: 6.150

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.